FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2760751501> ?p ?o ?g. }

• W2760751501 endingPage "E283" @default.
• W2760751501 startingPage "E282" @default.
• W2760751501 abstract "To evaluate whether a single-channel intracavitary applicator ( China Patent number:200710050108.1) which transformed from a traditional tandem applicator with a oval-shaped shield maded of high density alloy has the same clinical efficacy and safety as the standard Fletcher-type applicator in the high-dose-rate(HDR) brachytherapy for carcinoma of the cervix. From December 1st 2011 to December 1st 2014, 112 patients with cervix cancer were randomly assigned to the Patent applicator group (n=54) and the Fletcher applicator group(n=58). All but seven patients with early stage were treated with concurrent cisplatin chemotherapy and external beam radiotherapy (EBRT) followed by HDR brachytherapy. Whole pelvis irradiation was given with 6-MV photons via a four-field box variants or anterior and posterior parallel fields. The standard prescribed dose was 46 to 50 Gy, consisting of 23 to 25 fractions 5 to 6 weeks apart. Five to six fractions with a dose of 7 Gy per fraction of intracavitary brachytherapy at point A once a week were designed for all patients after the third week of pelvic irradiation.This regimen gives a total equivalent dose in 2-Gy fractions (EQD2) of 80-90 Gy to Point A. Chemotherapy was given with intravenous cisplatin 40 mg/m2 once a week during the EBRT. The acute toxicities and the late toxicities were evaluated according to the RTOG grading scale. The Kaplan-Meier analysis was used to compare the overall survival (OS), the progression-Free-Survival (PFS) and the local control (LC). The 2-year OS rate in the two groups was 72.4% in the Fletcher group and 83.2% in the Patent group, respectively. The 2-year PFS rate was 69.0% in the Fletcher group and 79.4% in the Patent group. The 2-year LC rate was 72.4% in the Fletcher group and 79.4% in the Patent group. The seriousness of acute treatment-related toxicities was similar in the two groups. 34 (58.6%) patients in the Fletcher group and 29 (53.7%) in the Patent group had Grade 3–4 hematologic toxicity. No Grade 4 nonhematologic toxicity was observed in the two groups. 5 (8.6%) patients in the Fletcher group and 10 (18.5%) in the Patent group had Grade 3 acute gastrointestinal toxicity. Grade 3 acute rectal reaction and genitourinary effect for the Fletcher group was both 1.7%, and for the Patent group was both 1.9%. The cumulative rate of late rectal complications for Grade 3–4 in the Fletcher group and the Patent group was 5.2% and 1.9%, respectively. The bladder late complications rate of Grade 3–4 was 1.7% for the Fletcher group, and no patients in the Patent group had serious bladder late complications． The early interim results of our study have shown that the patent single-channel intracavitary applicator may be able to provide a protection for the rectum and bladder, and has the same clinical efficacy as the standard Fletcher type three-channel applicator in the HDR brachytherapy for carcinoma of the cervix. Further studies are needed to assess long-term outcomes and associated toxicities." @default.
• W2760751501 created "2017-10-06" @default.
• W2760751501 creator A5008873401 @default.
• W2760751501 creator A5014912512 @default.
• W2760751501 creator A5016729352 @default.
• W2760751501 creator A5022326620 @default.
• W2760751501 creator A5032044745 @default.
• W2760751501 creator A5041032488 @default.
• W2760751501 creator A5041799910 @default.
• W2760751501 creator A5042718279 @default.
• W2760751501 creator A5052454962 @default.
• W2760751501 creator A5085902326 @default.
• W2760751501 date "2017-10-01" @default.
• W2760751501 modified "2023-09-27" @default.
• W2760751501 title "Early Interim Results of a Phase 2Clinical Trial of Brachytherapy With Single-Channel Applicator for Cervical Carcinoma" @default.
• W2760751501 doi "https://doi.org/10.1016/j.ijrobp.2017.06.1277" @default.
• W2760751501 hasPublicationYear "2017" @default.
• W2760751501 type Work @default.
• W2760751501 sameAs 2760751501 @default.
• W2760751501 citedByCount "0" @default.
• W2760751501 crossrefType "journal-article" @default.
• W2760751501 hasAuthorship W2760751501A5008873401 @default.
• W2760751501 hasAuthorship W2760751501A5014912512 @default.
• W2760751501 hasAuthorship W2760751501A5016729352 @default.
• W2760751501 hasAuthorship W2760751501A5022326620 @default.
• W2760751501 hasAuthorship W2760751501A5032044745 @default.
• W2760751501 hasAuthorship W2760751501A5041032488 @default.
• W2760751501 hasAuthorship W2760751501A5041799910 @default.
• W2760751501 hasAuthorship W2760751501A5042718279 @default.
• W2760751501 hasAuthorship W2760751501A5052454962 @default.
• W2760751501 hasAuthorship W2760751501A5085902326 @default.
• W2760751501 hasBestOaLocation W27607515011 @default.
• W2760751501 hasConcept C121608353 @default.
• W2760751501 hasConcept C126322002 @default.
• W2760751501 hasConcept C126894567 @default.
• W2760751501 hasConcept C141071460 @default.
• W2760751501 hasConcept C168563851 @default.
• W2760751501 hasConcept C2775908122 @default.
• W2760751501 hasConcept C2777088508 @default.
• W2760751501 hasConcept C2777416452 @default.
• W2760751501 hasConcept C2777740455 @default.
• W2760751501 hasConcept C2778220009 @default.
• W2760751501 hasConcept C2989005 @default.
• W2760751501 hasConcept C509974204 @default.
• W2760751501 hasConcept C61943457 @default.
• W2760751501 hasConcept C71924100 @default.
• W2760751501 hasConceptScore W2760751501C121608353 @default.
• W2760751501 hasConceptScore W2760751501C126322002 @default.
• W2760751501 hasConceptScore W2760751501C126894567 @default.
• W2760751501 hasConceptScore W2760751501C141071460 @default.
• W2760751501 hasConceptScore W2760751501C168563851 @default.
• W2760751501 hasConceptScore W2760751501C2775908122 @default.
• W2760751501 hasConceptScore W2760751501C2777088508 @default.
• W2760751501 hasConceptScore W2760751501C2777416452 @default.
• W2760751501 hasConceptScore W2760751501C2777740455 @default.
• W2760751501 hasConceptScore W2760751501C2778220009 @default.
• W2760751501 hasConceptScore W2760751501C2989005 @default.
• W2760751501 hasConceptScore W2760751501C509974204 @default.
• W2760751501 hasConceptScore W2760751501C61943457 @default.
• W2760751501 hasConceptScore W2760751501C71924100 @default.
• W2760751501 hasIssue "2" @default.
• W2760751501 hasLocation W27607515011 @default.
• W2760751501 hasOpenAccess W2760751501 @default.
• W2760751501 hasPrimaryLocation W27607515011 @default.
• W2760751501 hasRelatedWork W2513916013 @default.
• W2760751501 hasRelatedWork W2942848944 @default.
• W2760751501 hasRelatedWork W2966036943 @default.
• W2760751501 hasRelatedWork W3029213237 @default.
• W2760751501 hasRelatedWork W3031343993 @default.
• W2760751501 hasRelatedWork W3104537559 @default.
• W2760751501 hasRelatedWork W4206581437 @default.
• W2760751501 hasRelatedWork W4237106564 @default.
• W2760751501 hasRelatedWork W4313546044 @default.
• W2760751501 hasRelatedWork W4364377845 @default.
• W2760751501 hasVolume "99" @default.
• W2760751501 isParatext "false" @default.
• W2760751501 isRetracted "false" @default.
• W2760751501 magId "2760751501" @default.
• W2760751501 workType "article" @default.